SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York. Show more

31 East 62nd Street, New York, NY, 10065, United States

Drug Manufacturers - Specialty & Generic

Healthcare

Market Cap

353.9M

52 Wk Range

$4.81 - $9.62

Previous Close

$4.94

Open

$5.06

Volume

793,100

Day Range

$4.86 - $5.06

Enterprise Value

199.6M

Cash

155M

Avg Qtr Burn

-16.86M

Insider Ownership

43.34%

Institutional Own.

52.00%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TPOXX (Intravenous) Details Smallpox, Vaccine	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TPOXX® (tecovirimat) Details Smallpox	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.